Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: A retrospective cohort study

Dong Hyun Oh, Jung Ju Kim, Jinnam Kim, Hye Seong, Se Ju Lee, Yong Chan Kim, Eun Jin Kim, In Young Jung, Woo Yong Jeong, Su Jin Jeong, Nam Su Ku, Sang Hoon Han, Jun Yong Choi, Young Goo Song, June Myung Kim

Research output: Contribution to journalArticle

Abstract

Background: Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with β-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. Methods: Patients with MSSA bacteremia recruited from a tertiary referral hospital were enrolled in this retrospective cohort study. Demographic characteristics, laboratory data, and clinical outcome of the treatment were compared between a group receiving nafcillin and a group receiving glycopeptides. Results: A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). Conclusion: In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.

Original languageEnglish
Article number60
JournalBMC Infectious Diseases
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Jan 30

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: A retrospective cohort study'. Together they form a unique fingerprint.

  • Cite this

    Oh, D. H., Kim, J. J., Kim, J., Seong, H., Lee, S. J., Kim, Y. C., Kim, E. J., Jung, I. Y., Jeong, W. Y., Jeong, S. J., Ku, N. S., Han, S. H., Choi, J. Y., Song, Y. G., & Kim, J. M. (2018). Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: A retrospective cohort study. BMC Infectious Diseases, 18(1), [60]. https://doi.org/10.1186/s12879-018-2978-z